The potential of circulating nucleic acids as components of companion diagnostics for predicting and monitoring chemotherapy response.

摘要: An effective personalized medicine is associated with the ability of identifying cancer patients who respond to anticancer targeted therapies. Therefore, new companion biomarkers that facilitate drug development are urgently needed. Since clinically relevant genetic and epigenetic alterations can be detected in cell-free nucleic acids blood circulation patients, these molecules may a promising class potential liquid biomarkers. They obtained real-time from blood, their analyses could, consequently, treatment decisions. Screening biopsies provide information on aberrant signaling pathway should blocked by chosen therapy. This article will discuss circulating as therapeutics for overcoming chemotherapeutic resistance strategies.